Media stories about T2 Biosystems (NASDAQ:TTOO) have trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. T2 Biosystems earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media headlines about the medical equipment provider an impact score of 46.5204445798529 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the media headlines that may have impacted Accern Sentiment’s rankings:

TTOO has been the topic of several research reports. Cantor Fitzgerald dropped their price target on T2 Biosystems from $7.00 to $6.00 and set an “overweight” rating on the stock in a report on Wednesday, May 3rd. Zacks Investment Research raised T2 Biosystems from a “sell” rating to a “hold” rating in a report on Saturday, May 6th. Finally, BTIG Research raised T2 Biosystems from a “sell” rating to a “neutral” rating and set a $4.00 price target on the stock in a report on Monday, May 8th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $6.75.

T2 Biosystems (TTOO) traded up 9.79% on Monday, hitting $3.59. The company’s stock had a trading volume of 139,904 shares. The company’s market capitalization is $110.44 million. T2 Biosystems has a 1-year low of $2.50 and a 1-year high of $8.04. The company has a 50 day moving average price of $2.94 and a 200-day moving average price of $4.35.

T2 Biosystems (NASDAQ:TTOO) last announced its quarterly earnings data on Thursday, August 3rd. The medical equipment provider reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by $0.01. T2 Biosystems had a negative net margin of 1,473.71% and a negative return on equity of 178.83%. The business had revenue of $0.96 million during the quarter, compared to the consensus estimate of $0.79 million. On average, equities analysts forecast that T2 Biosystems will post ($1.93) earnings per share for the current fiscal year.

In other T2 Biosystems news, Director David B. Elsbree acquired 10,000 shares of T2 Biosystems stock in a transaction on Tuesday, June 6th. The shares were purchased at an average cost of $3.50 per share, with a total value of $35,000.00. Following the completion of the purchase, the director now owns 50,000 shares in the company, valued at $175,000. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders acquired 20,000 shares of company stock worth $70,330. Insiders own 38.70% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “T2 Biosystems (NASDAQ:TTOO) Getting Somewhat Positive Media Coverage, Study Shows” was reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at

About T2 Biosystems

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).

Insider Buying and Selling by Quarter for T2 Biosystems (NASDAQ:TTOO)

Receive News & Ratings for T2 Biosystems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.